Back to Newsroom

Preclinical Study Suggests That Solithromycin May Provide an Effective Antimicrobial Approach for Prevention and Treatment of Intrauterine Infections in Pregnancy

CHAPEL HILL, N.C., Nov. 18, 2013 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of an in vivo preclinical study suggesting that solithromycin (CEM-101) may provide an effective antimicrobial approach for the prevention and treatment of intrauterine infections during pregnancy. Intravenous administration of solithromycin in pregnant sheep, a validated model for human pregnancy, resulted in effective concentrations of the drug in fetal plasma and amniotic fluid. The study will be presented at the 8th World Congress on Developmental Origins of Health and Disease (DOHaD) Conference on Nov. 18, in Singapore. The research has also been accepted for publication in Antimicrobial Agents and Chemotherapy and it is currently available online.